Xilio Therapeutics, Inc. XLO
7.56 USD -0.08 (-1.11%)
Regular-session close
7.56 0.00 0.00%
After hours · Nov 20, 4:00 PM ET
7.07 Day range 7.60
6.47 52-week range 10.71
- YTD
- -15.63%
- 1 year
- -28.00%
News
benzinga.com Xilio Therapeutics Q3 EPS $(0.30) Beats $(0.82) Estimate, Sales $9.984M Beat $4.840M Estimate Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.82) by 63.41 percent. This is a 81.01 percent increase over losses of…
benzinga.com Xilio Therapeutics Doses First Participant In Its Phase 1/2 Clinical Study Of XTX501 To Treat Metastatic Non-Small Cell Lung Cancer Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that the…
benzinga.com Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16 Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.
